Nele Henrike Thomas

ORCID: 0000-0003-1133-0171
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Amyotrophic Lateral Sclerosis Research
  • Prostate Cancer Diagnosis and Treatment
  • Cardiovascular Function and Risk Factors
  • Statistical Methods in Clinical Trials
  • Advanced Causal Inference Techniques
  • Diabetes Treatment and Management
  • Prostate Cancer Treatment and Research
  • Advanced Radiotherapy Techniques
  • Heart Failure Treatment and Management
  • Neurogenetic and Muscular Disorders Research
  • Health Systems, Economic Evaluations, Quality of Life

Medizinische Hochschule Hannover
2022-2025

DIGIT-HF is a multicentre, randomized, double-blind, placebo-controlled trial designed to investigate the effect of digitoxin versus placebo on composite primary endpoint time all-cause death and hospital admission for worsening heart failure (HFH) (whichever occurs first) in patients with (HF) reduced ejection fraction (HFrEF).1 The conducted compliance German Drug Law (AMG), Good Clinical Practice (GCP) ordinance, ICH GCP guidelines, other applicable ethical regulatory requirements....

10.1002/ejhf.3575 article EN cc-by-nc European Journal of Heart Failure 2025-01-21

Abstract Objective Fatigue is a common and burdensome symptom of spinal muscular atrophy. Given its complex interactions, different dimensions fatigue need to be investigated. The Multidimensional Inventory widely used instrument that captures five distinct dimensions. aim this study was investigate the validity reliability German in atrophy evaluate presence clinically relevant fatigue. Methods One hundred forty adult patients completed nationwide, multicenter, cross‐sectional study....

10.1002/acn3.51520 article EN Annals of Clinical and Translational Neurology 2022-02-22

Abstract Formal proof of efficacy a drug requires that in prospective experiment, superiority over placebo, or either at least non‐inferiority to an established standard, is demonstrated. Traditionally one primary endpoint specified, but various diseases exist where treatment success needs be based on the assessment two endpoints. With co‐primary endpoints, both need “significant” as prerequisite claim study success. Here, no adjustment study‐wise type‐1‐error needed, sample size often...

10.1002/pst.2314 article EN cc-by Pharmaceutical Statistics 2023-05-22

Radiotherapy for prostate cancer is often preceded by neoadjuvant androgen deprivation therapy (ADT), which leads to a reduction in the size of prostate. This study examines whether it relevant treatment planning acquire second magnetic resonance imaging (MRI) after ADT (=MRI 2) or can be planned without disadvantage based on an MRI acquired before starting 1). The data radiotherapy 17 patients with who received two MRIs (before and ADT) were analyzed as follows: detailed comparable...

10.3390/jcm12020574 article EN Journal of Clinical Medicine 2023-01-10
Coming Soon ...